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Background
The only malaria vaccine to have been tested in Phase III
clinical vaccine trials [1] induces protection which has
been associated with high titres of antibodies against
sporozoites. Efficacy against clinical malaria in infants of
5-17 months and 6-12 weeks was 55.8% and 31.3%
respectively. A successful malaria vaccine will likely need
to induce both cellular and humoral immunity in order
to achieve a deployable level of efficacy in the target age
groups. Prime-boost immunisation with viral vectors
ChAd63 and MVA, both encoding ME-TRAP, has been
shown to induce high T cell responses and modest anti-
body responses to the pre-erythrocytic malaria antigen
TRAP. A Phase II study with this vaccine regime in
malaria-naïve adults showed significant efficacy, which
correlated with frequency of monofunctional CD8+ T
cells secreting IFNg. TRAP antibody titres were modest
and did not correlate with protection [2]. In contrast to
this, high titres of vaccine-induced anti-TRAP antibodies
are measured in infants in malaria-endemic settings.
Materials and methods
Antibody titres were measured in 138 malaria-exposed chil-
dren vaccinated with ChAd63 MVA ME-TRAP in three
Phase I studies in The Gambia and Burkina Faso. Age
groups at first immunisation were 2-6 years, 5-12 months
and 10 weeks in The Gambia and 5-17 months in Burkina
Faso. Avidity and isotype profiles were also analyzed.
Results
Antibody responses to TRAP were significantly higher in
10 week old and 5-12 month old infants in The Gambia
and 5-17 month old infants in Burkina Faso compared
to 2-6 year old children and adults in The Gambia and
malaria-naïve UK adults. IgG isotype responses were
predominantly IgG1 and IgG3 and we also detected IgA
and IgM. TRAP-specific IgG avidity was significantly
higher in Burkinabe infants aged 5-17 months and Gam-
bian infants aged 5-12 months compared to Gambian
adults and 2-6 year old children. TRAP-specific IgG1
avidity significantly correlated with age at vaccination in
5-17 month old Burkinabe infants and was significantly
higher than in 10 week old Gambian infants. Functional
activity of anti-TRAP antibodies will be analysed in vitro
using a sporozoite invasion inhibition assay.
Conclusions
We demonstrate excellent humoral immunogenicity in
key target populations vaccinated with a pre-erythrocytic
malaria vaccination regime, exceeding that seen in UK
malaria-naïve adults.
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